Results from OS analysis of KATE2 study of atezolizumab plus T-DM1 in HER2+ advanced BC Oct. 10, 2019
Novel bispecific antibody 4224 shows in vivo efficacy in tumors expressing high levels of EpCAM Oct. 10, 2019